Romark announced initial results from a phase 3 trial evaluating NT-300 (nitazoxanide extended-release tablets, 300 mg) versus placebo as a treatment for mild or moderate…
Five months after making an upfront payment of $425 million in cash to acquire OncImmune and its phase 3 COVID-19 therapeutic, CD24Fc, Merck announced it…
Although TrialSite just reported on the temporary halt of COVID-19 vaccinations ordered by the U.S. Drug Administration (FDA) and the Centers for Disease Control (CDC) in…
A Kaiser Permanente study reveals that regular, consistent exercise activity associates with a lowered risk of severe COVID-19. Recently published in the British Journal of Sports…
Important glaucoma-based research led by investigators at NYU Grossman School of Medicine reveals that a chemical known to protect nerve cells actually slows down the…
How can we make cancer-focused clinical trials more inclusive while also raising the quality of overall research? That sounds like a win-win value proposition. But…
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into an…
A group of dedicated physicians recently came together to send an open letter to the medical journal JAMA. Their purpose: to declare that the recent…
Vaccines out of China were produced, and approved, rapidly but actual transparency into true efficacy has been more challenging but recently the results of a…
The University of Sydney, Technovalia, and Vax4COVID recently shared their ethics committee has authorized the greenlight of a Phase 1 clinical trial of the COVIGEN COVID-19…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
